Rhythm Pharmaceuticals, Inc. (RYTM)

Trade RYTM now with
7/20/2020 7:41:42 AM Rhythm Pharma Appoints David Meeker As CEO
7/1/2020 8:12:49 AM Rhythm Receives Rare Pediatric Disease Designation From FDA For Setmelanotide
3/30/2020 7:59:22 AM Rhythm Completes Rolling Submission Of NDA For Setmelanotide
3/18/2020 8:16:02 AM Rhythm Receives Orphan Drug Designation From FDA For Setmelanotide For Treatment Of Alström Syndrome
10/16/2019 12:14:56 AM Rhythm Pharma Prices Public Offering Of 8.11 Mln Shares At $18.50/Shr
9/9/2019 7:41:46 AM Rhythm Plans To Expand Phase 2 Basket Study Evaluating Setmelanotide
8/7/2019 7:28:19 AM Rhythm Meets End Points From Pivotal Phase 3 Clinical Trials Of Setmelanotide In POMC And LEPR Deficiency Obesities
7/29/2019 8:03:21 AM Rhythm Pharma Says Positive Opinion By EMA On Orphan Drug Designation For Setmelanotide For Bardet-Biedl Syndrome
12/13/2018 7:05:53 AM Rhythm Pharma Says First Patient Enrolled In Pivotal Phase 3 Clinical Trial Of Setmelanotide
11/9/2018 8:12:28 AM Rhythm Pharma Q3 Net Loss $17.7 Mln Or $0.52/shr Vs Net Loss $11.4 Mln Or $1.78/shr Last Year
10/15/2018 8:04:48 AM Rhythm Pharma Appoints Murray Stewart As Chief Medical Officer
10/5/2018 12:36:21 AM This Day That Year: Rhythm Pharma
7/23/2018 8:07:06 AM Rhythm Pharma Gets EMA PRIME Designation For Setmelanotide In Rare Genetic Disorders Of Obesity
6/25/2018 4:05:25 PM Rhythm Pharmaceuticals Closes Public Offering Of 6.59 Mln Shares At $26.42/share
6/20/2018 9:41:14 PM Rhythm Pharma Prices Public Offering Of 5.732 Mln Shares At $26.42/shr
6/18/2018 7:09:09 AM Rhythm Announces New Topline Clinical Data From Ongoing Phase 2 Basket Studies Of Setmelanotide